Charles Bennett to Neoplasms
This is a "connection" page, showing publications Charles Bennett has written about Neoplasms.
Connection Strength
7.886
-
Progressive multifocal leukoencephalopathy in patients treated with rituximab: a 20-year review from the Southern Network on Adverse Reactions. Lancet Haematol. 2021 Aug; 8(8):e593-e604.
Score: 0.342
-
The First 2?Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse Reactions. Oncologist. 2021 08; 26(8):e1418-e1426.
Score: 0.333
-
Contemporary Clinical Trials Office: Doing More With Less. JCO Oncol Pract. 2021 01; 17(1):1-2.
Score: 0.328
-
Improving oncology biosimilar launches in the EU, the USA, and Japan: an updated Policy Review from the Southern Network on Adverse Reactions. Lancet Oncol. 2020 12; 21(12):e575-e588.
Score: 0.327
-
End of an era of administering erythropoiesis stimulating agents among Veterans Administration cancer patients with chemotherapy-induced anemia. PLoS One. 2020; 15(6):e0234541.
Score: 0.317
-
Improving the Evidence Base for Delivery of High-Quality Cancer Care. JAMA Oncol. 2017 08 01; 3(8):1029-1031.
Score: 0.259
-
Consensus on the Existence of Functional Erythropoietin Receptors on Cancer Cells. JAMA Oncol. 2016 Jan; 2(1):134-6.
Score: 0.232
-
Japanese regulatory authority's perspective on biosimilars - authors' reply. Lancet Oncol. 2015 Mar; 16(3):e102.
Score: 0.219
-
Regulatory and clinical considerations for biosimilar oncology drugs. Lancet Oncol. 2014 Dec; 15(13):e594-e605.
Score: 0.215
-
Toxicity and costs of toxicity associated with new cancer drugs: international implications. J Clin Oncol. 2014 Nov 10; 32(32):3591-2.
Score: 0.213
-
Erythropoiesis-stimulating agents and quality of life: personal journeys of a cancer survivor, oncologist, and two cancer health services researchers. Br J Cancer. 2014 Jul 29; 111(3):421-3.
Score: 0.211
-
Forewarned is forearmed: erythropoietin use in CKD patients with cancer. J Nephrol. 2013 Sep-Oct; 26(5):805-6.
Score: 0.198
-
Colony-stimulating factors for febrile neutropenia. N Engl J Med. 2013 07 18; 369(3):286.
Score: 0.196
-
Colony-stimulating factors for febrile neutropenia during cancer therapy. N Engl J Med. 2013 Mar 21; 368(12):1131-9.
Score: 0.192
-
A review of safety, efficacy, and utilization of erythropoietin, darbepoetin, and peginesatide for patients with cancer or chronic kidney disease: a report from the Southern Network on Adverse Reactions (SONAR). Semin Thromb Hemost. 2012 Nov; 38(8):783-96.
Score: 0.187
-
Thromboprophylaxis guidelines in cancer with a primary focus on ambulatory patients receiving chemotherapy: a review from the Southern Network on Adverse Reactions (SONAR). Semin Thromb Hemost. 2012 Nov; 38(8):759-67.
Score: 0.187
-
Reassessments of ESAs for cancer treatment in the US and Europe. Oncology (Williston Park). 2010 Mar; 24(3):260-8.
Score: 0.155
-
Partnering to promote equality in cancer care. Soc Work Public Health. 2009 Jul-Aug; 24(4):355-9.
Score: 0.148
-
Providing cancer care to a graying and diverse cancer population in the 21st century: are we prepared? J Clin Oncol. 2009 Jun 10; 27(17):2745-6.
Score: 0.146
-
Intersecting guidelines: administering erythropoiesis-stimulating agents to chronic kidney disease patients with cancer. Semin Dial. 2009 Jan-Feb; 22(1):1-4.
Score: 0.142
-
Treatment success in cancer: new cancer treatment successes identified in phase 3 randomized controlled trials conducted by the National Cancer Institute-sponsored cooperative oncology groups, 1955 to 2006. Arch Intern Med. 2008 Mar 24; 168(6):632-42.
Score: 0.136
-
Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA. 2008 Feb 27; 299(8):914-24.
Score: 0.135
-
Does reimbursement affect physicians' decision making? Examples from the use of recombinant erythropoietin. Cancer Treat Res. 2008; 140:235-51.
Score: 0.133
-
Cancer-associated neutropenic fever: clinical outcome and economic costs of emergency department care. Oncologist. 2007 Aug; 12(8):1019-26.
Score: 0.130
-
Granulocyte-colony stimulating factor administration to healthy individuals and persons with chronic neutropenia or cancer: an overview of safety considerations from the Research on Adverse Drug Events and Reports project. Bone Marrow Transplant. 2007 Aug; 40(3):185-92.
Score: 0.128
-
Cost considerations in the management of cancer in the older patient. Oncology (Williston Park). 2007 Jun; 21(7):851-7; discussion 858, 860, 862 passim.
Score: 0.128
-
Evaluating the total costs of chemotherapy-induced febrile neutropenia: results from a pilot study with community oncology cancer patients. Oncologist. 2007 Apr; 12(4):478-83.
Score: 0.127
-
Reducing adverse drug events in the outpatient chemotherapy setting: attention must be paid. Cancer. 2005 Dec 01; 104(11):2289-91.
Score: 0.116
-
The blue cross blue shield assessment technology review: summary of findings. Best Pract Res Clin Haematol. 2005; 18(3):423-31.
Score: 0.108
-
Effectiveness of erythropoietin in the treatment of patients with malignancies: methods and preliminary results of a Cochrane review. Best Pract Res Clin Haematol. 2005; 18(3):449-54.
Score: 0.108
-
Estimating the cost of cancer: results on the basis of claims data analyses for cancer patients diagnosed with seven types of cancer during 1999 to 2000. J Clin Oncol. 2004 Sep 01; 22(17):3524-30.
Score: 0.106
-
Use of erythropoietin in cancer patients: assessment of oncologists' practice patterns in the United States and other countries. Am J Med. 2004 Jan 01; 116(1):28-34.
Score: 0.101
-
Evaluating the total costs of cancer. The Northwestern University Costs of Cancer Program. Oncology (Williston Park). 2003 Jan; 17(1):109-14; discussion 119-21.
Score: 0.094
-
Clinical trials: are they a good buy? J Clin Oncol. 2001 Dec 01; 19(23):4330-9.
Score: 0.088
-
Comparison and impact of COVID-19 for patients with cancer: a survival analysis of fatality rate controlling for age, sex and cancer type. BMJ Health Care Inform. 2021 May; 28(1).
Score: 0.084
-
Evaluating the financial impact of clinical trials in oncology: results from a pilot study from the Association of American Cancer Institutes/Northwestern University clinical trials costs and charges project. J Clin Oncol. 2000 Aug; 18(15):2805-10.
Score: 0.080
-
Does reimbursement affect physician decision making? Cancer Treat Res. 2000; 102:137-49.
Score: 0.077
-
Quality improvement: carrots or sticks? J Clin Oncol. 1999 Dec; 17(12):3856-60.
Score: 0.076
-
Use of hematopoietic colony-stimulating factors: comparison of the 1994 and 1997 American Society of Clinical Oncology surveys regarding ASCO clinical practice guidelines. Health Services Research Committee of the American Society of Clinical Oncology. J Clin Oncol. 1999 Nov; 17(11):3676-81.
Score: 0.076
-
Regulatory and Clinical Experiences with Biosimilar Filgrastim in the U.S., the European Union, Japan, and Canada. Oncologist. 2019 04; 24(4):537-548.
Score: 0.072
-
Growth of oncology physician practice management companies. Cancer Invest. 1999; 17(5):362-70.
Score: 0.072
-
Cancer insurance policies in Japan and the United States. West J Med. 1998 Jan; 168(1):17-22.
Score: 0.067
-
Effects of the US Food and Drug Administration Boxed Warning of Erythropoietin-Stimulating Agents on Utilization and Adverse Outcome. J Clin Oncol. 2017 Jun 10; 35(17):1945-1951.
Score: 0.064
-
Economic analyses in clinical trials for cooperative groups: operational considerations. Cancer Invest. 1997; 15(5):448-53.
Score: 0.062
-
Interpretation of surrogate endpoints in the era of the 21st Century Cures Act. BMJ. 2016 Dec 30; 355:i6286.
Score: 0.062
-
Use of hematopoietic colony-stimulating factors: the American Society of Clinical Oncology survey. The Health Services Research Committee of the American Society of Clinical Oncology. J Clin Oncol. 1996 Sep; 14(9):2511-20.
Score: 0.061
-
Detection of cases of progressive multifocal leukoencephalopathy associated with new biologicals and targeted cancer therapies from the FDA's adverse event reporting system. Expert Opin Drug Saf. 2016 Aug; 15(8):1003-11.
Score: 0.060
-
Economic analysis during phase III clinical trials: who, what, when, where, and why? Oncology (Williston Park). 1995 Nov; 9(11 Suppl):169-75.
Score: 0.057
-
Free-riding and the prisoner's dilemma: problems in funding economic analyses of phase III cancer clinical trials. J Clin Oncol. 1995 Sep; 13(9):2457-63.
Score: 0.057
-
Economic analyses of clinical trials in cancer: are they helpful to policy makers? Stem Cells. 1994 Jul; 12(4):424-9.
Score: 0.052
-
Studying cancer-related fatigue: report of the NCCN scientific research committee. J Natl Compr Canc Netw. 2010 Dec; 8(12):1331-9.
Score: 0.041
-
American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. Blood. 2010 Nov 18; 116(20):4045-59.
Score: 0.041
-
American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. J Clin Oncol. 2010 Nov 20; 28(33):4996-5010.
Score: 0.041
-
Association between pharmaceutical support and basic science research on erythropoiesis-stimulating agents. Arch Intern Med. 2010 Sep 13; 170(16):1490-8.
Score: 0.040
-
Accelerated approval of cancer drugs: improved access to therapeutic breakthroughs or early release of unsafe and ineffective drugs? J Clin Oncol. 2009 Sep 10; 27(26):4398-405.
Score: 0.037
-
Quality of reporting of serious adverse drug events to an institutional review board: a case study with the novel cancer agent, imatinib mesylate. Clin Cancer Res. 2009 Jun 01; 15(11):3850-5.
Score: 0.037
-
A health services research agenda for cellular, molecular and genomic technologies in cancer care. Public Health Genomics. 2009; 12(4):233-44.
Score: 0.036
-
Venous thromboembolic disease. NCCN. Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2008 Sep; 6(8):716-53.
Score: 0.035
-
Cancer- and chemotherapy-induced anemia. J Natl Compr Canc Netw. 2008 Jul; 6(6):536-64.
Score: 0.035
-
Dermatologic challenges in cancer patients and survivors. Oncology (Williston Park). 2007 Nov; 21(12):1462-72; discussion 1473, 1476, 1481 passim.
Score: 0.033
-
Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update. Blood. 2008 Jan 01; 111(1):25-41.
Score: 0.033
-
Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update. J Clin Oncol. 2008 Jan 01; 26(1):132-49.
Score: 0.033
-
Thalidomide- and lenalidomide-associated thromboembolism among patients with cancer. JAMA. 2006 Dec 06; 296(21):2558-60.
Score: 0.031
-
Hyponatremia and other toxic effects during a phase I trial of recombinant human gamma interferon and vinblastine. Cancer Treat Rep. 1986 Sep; 70(9):1081-4.
Score: 0.030
-
Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst. 2006 May 17; 98(10):708-14.
Score: 0.030
-
Recombinant human erythropoietin and overall survival in cancer patients: results of a comprehensive meta-analysis. J Natl Cancer Inst. 2005 Apr 06; 97(7):489-98.
Score: 0.028
-
Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. Blood. 2002 Oct 01; 100(7):2303-20.
Score: 0.023
-
Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol. 2001 Mar 01; 19(5):1519-38.
Score: 0.021
-
Feasibility and effectiveness of the NEST13+ as a screening tool for advanced illness care needs. J Palliat Med. 2010 Feb; 13(2):161-9.
Score: 0.010
-
2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol. 2006 Jul 01; 24(19):3187-205.
Score: 0.007